Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Auris Medical (NASDAQ:EARS) Stock Price

News coverage about Auris Medical (NASDAQ:EARS) has trended somewhat positive on Thursday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Auris Medical earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 47.4822697778921 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:

Separately, Zacks Investment Research lowered shares of Auris Medical from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th.

Shares of Auris Medical (NASDAQ:EARS) remained flat at $$0.48 during midday trading on Thursday. The company had a trading volume of 551,400 shares, compared to its average volume of 1,126,243. The stock has a market cap of $22.81, a P/E ratio of -0.74 and a beta of 0.61. Auris Medical has a 1 year low of $0.38 and a 1 year high of $1.39. The company has a debt-to-equity ratio of -14.04, a current ratio of 1.86 and a quick ratio of 1.86.

TRADEMARK VIOLATION WARNING: This article was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://stocknewstimes.com/2018/01/11/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-auris-medical-ears-share-price.html.

About Auris Medical

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Insider Buying and Selling by Quarter for Auris Medical (NASDAQ:EARS)

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply